Earnings Beat Muted by Guidance Cut: Social media erupted following Abbott Laboratories' first-quarter results, where adjusted earnings and revenue surpassed estimates but a reduced full-year outlook due to a mild flu season and acquisition costs overshadowed the positives. Investors highlighted the impact on diagnostic sales, sparking debates on short-term pressures. Many noted the Exact Sciences deal as a long-term growth catalyst despite near-term drags.
Stock Plunge Sparks Buy Signals: Shares tumbled nearly 7% post-earnings, prompting traders to weigh in on potential rebounds. Some pointed to elevated price targets from analysts around $120, viewing insider selling as noise amid bullish technicals. Discussions reflected optimism for a rotation into healthcare defensives amid market volatility.
Recovery Hopes Emerge: Recent chatter suggests bargain hunting at current levels near $96, with calls for a push toward $100-$105. Commentators emphasized resilient core growth prospects beyond temporary headwinds. Sentiment tilts toward viewing the dip as an entry point for patient investors.
Note: This discussion summary was generated from an AI condensation of post data.
Abbott Laboratories Insider Trading Activity
Abbott Laboratories insiders have traded $ABT stock on the open market 10 times in the past 6 months. Of those trades, 3 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $ABT stock by insiders over the last 6 months:
- ROBERT B FORD (CHAIRMAN AND CEO) purchased 18,800 shares for an estimated $2,013,966
- DANIEL J STARKS has made 2 purchases buying 10,000 shares for an estimated $1,087,331 and 0 sales.
- ERIC SHROFF (Senior Vice President) has made 0 purchases and 2 sales selling 2,295 shares for an estimated $284,988.
- LOUIS H. MORRONE (EXECUTIVE VICE PRESIDENT) sold 1,144 shares for an estimated $132,223
- DANIEL GESUA SIVE SALVADORI (EVP AND GROUP PRESIDENT) sold 885 shares for an estimated $102,288
- MARY K MORELAND (EXECUTIVE VICE PRESIDENT) sold 613 shares for an estimated $70,850
- JOHN A. JR. MCCOY (VICE PRESIDENT AND CONTROLLER) sold 585 shares for an estimated $67,614
- ELIZABETH C. CUSHMAN (EVP, GC AND SECRETARY) sold 263 shares for an estimated $30,397
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Abbott Laboratories Revenue
Abbott Laboratories had revenues of $11.2B in Q1 2026. This is an increase of 7.78% from the same period in the prior year.
You can track ABT financials on Quiver Quantitative's ABT stock page.
Abbott Laboratories Congressional Stock Trading
Members of Congress have traded $ABT stock 11 times in the past 6 months. Of those trades, 4 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $ABT stock by members of Congress over the last 6 months:
- REPRESENTATIVE RICHARD MCCORMICK has traded it 2 times. They made 2 purchases worth up to $30,000 on 03/19, 11/05 and 0 sales.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 3 times. They made 1 purchase worth up to $15,000 on 11/18 and 2 sales worth up to $30,000 on 02/10, 12/19.
- REPRESENTATIVE THOMAS H. KEAN, JR. purchased up to $15,000 on 01/29.
- REPRESENTATIVE JULIE JOHNSON has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 12/18, 11/13.
- REPRESENTATIVE JULIA LETLOW sold up to $15,000 on 12/08.
- REPRESENTATIVE BYRON DONALDS has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 12/04.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Abbott Laboratories Hedge Fund Activity
We have seen 1,247 institutional investors add shares of Abbott Laboratories stock to their portfolio, and 1,608 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- J. STERN & CO. LLP added 39,005,451 shares (+12439.6%) to their portfolio in Q4 2025, for an estimated $4,886,992,955
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 30,767,022 shares (-73.6%) from their portfolio in Q4 2025, for an estimated $3,854,800,186
- JPMORGAN CHASE & CO removed 7,190,072 shares (-24.5%) from their portfolio in Q4 2025, for an estimated $900,844,120
- ALLIANCEBERNSTEIN L.P. added 6,926,031 shares (+125.3%) to their portfolio in Q4 2025, for an estimated $867,762,423
- BLACKROCK, INC. added 5,348,812 shares (+3.8%) to their portfolio in Q4 2025, for an estimated $670,152,655
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 4,993,343 shares (-28.1%) from their portfolio in Q4 2025, for an estimated $625,615,944
- POLEN CAPITAL MANAGEMENT LLC removed 3,458,374 shares (-46.6%) from their portfolio in Q4 2025, for an estimated $433,299,678
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Abbott Laboratories Government Contracts
We have seen $126,730,028 of award payments to $ABT over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- VISN1 BPA FOR IMMUNOCHEMISTRY CPRR TESTING ADDING EQUIPMENT FOR MANCHESTER NH VAMC - WITHIN ORIGINAL SCOPE: $4,335,000
- CHEMISTRY IMMUNOASSAY ANALYZER COST PER REPORTABLE RESULT (CPRR) PRICE SCHEDULE UPDATE: $4,000,483
- LAB CHEMISTRY SERVICES: $3,620,964
- EXERCISING OPTION YEAR 2: $2,600,297
- CHEMISTRY ANALYZERS.: $2,351,823
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Abbott Laboratories Analyst Ratings
Wall Street analysts have issued reports on $ABT in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 02/02/2026
- BTIG issued a "Buy" rating on 01/23/2026
To track analyst ratings and price targets for Abbott Laboratories, check out Quiver Quantitative's $ABT forecast page.
Abbott Laboratories Price Targets
Multiple analysts have issued price targets for $ABT recently. We have seen 12 analysts offer price targets for $ABT in the last 6 months, with a median target of $120.5.
Here are some recent targets:
- Matt Miksic from Barclays set a target price of $143.0 on 04/20/2026
- Adam Maeder from Piper Sandler set a target price of $115.0 on 04/17/2026
- Suraj Kalia from Oppenheimer set a target price of $115.0 on 04/17/2026
- Vijay Kumar from Evercore ISI Group set a target price of $120.0 on 04/17/2026
- Bruce D. Jackson from Benchmark set a target price of $120.0 on 04/17/2026
- Shagun Singh from RBC Capital set a target price of $130.0 on 04/17/2026
- Rick Wise from Stifel set a target price of $120.0 on 04/17/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
